Veracyte [VCYT] vs Danaher [DHR] Detailed Stock Comparison
Veracyte
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Veracyte wins in 6 metrics, Danaher wins in 13 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Veracyte | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.29 | 41.85 | Danaher |
| Price-to-Book Ratio | 1.55 | 2.70 | Veracyte |
| Debt-to-Equity Ratio | 4.23 | 35.45 | Veracyte |
| PEG Ratio | 59.10 | 23.52 | Danaher |
| EV/EBITDA | 25.92 | 20.84 | Danaher |
| Profit Margin (TTM) | 7.13% | 14.21% | Danaher |
| Operating Margin (TTM) | 7.03% | 20.12% | Danaher |
| EBITDA Margin (TTM) | 7.03% | 20.12% | Danaher |
| Return on Equity | 2.86% | 6.68% | Danaher |
| Return on Assets (TTM) | 1.94% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $63.81M | $5.30B | Danaher |
| 1-Year Return | 9.44% | -28.78% | Veracyte |
| Price-to-Sales Ratio (TTM) | 4.00 | 5.88 | Veracyte |
| Enterprise Value | $1.61B | $156.73B | Danaher |
| EV/Revenue Ratio | 3.48 | 6.53 | Veracyte |
| Gross Profit Margin (TTM) | 69.46% | 59.35% | Veracyte |
| Revenue per Share (TTM) | $6 | $33 | Danaher |
| Earnings per Share (Diluted) | $0.42 | $4.71 | Danaher |
| Beta (Stock Volatility) | 2.07 | 0.80 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Veracyte vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Veracyte | 0.55% | -6.38% | -13.47% | -20.43% | -47.54% | -41.54% |
| Danaher | -0.04% | -4.08% | -1.99% | 0.19% | -8.01% | -14.24% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Veracyte | 9.44% | -15.27% | -26.92% | 135.22% | 92.20% | 92.20% |
| Danaher | -28.78% | -23.34% | 8.24% | 222.04% | 651.39% | 946.68% |
Performance & Financial Health Analysis: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.85B | $141.13B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,218,800 | 5,971,700 |
| 90 Day Avg. Volume | 1,752,003 | 4,520,667 |
| Last Close | $23.64 | $197.09 |
| 52 Week Range | $19.73 - $47.32 | $171.00 - $281.70 |
| % from 52W High | -50.04% | -30.04% |
| All-Time High | $86.03 (Feb 08, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -72.52% | -33.43% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.03% |
| Quarterly Earnings Growth | 0.18% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.14% |
| Operating Margin (TTM) | 0.07% | 0.20% |
| Return on Equity (TTM) | 0.03% | 0.07% |
| Debt to Equity (MRQ) | 4.23 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.26 | $73.10 |
| Cash per Share (MRQ) | $3.67 | $4.13 |
| Operating Cash Flow (TTM) | $89.42M | $6.17B |
| Levered Free Cash Flow (TTM) | $76.93M | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.29 | 41.85 |
| Forward P/E | 59.10 | 23.52 |
| PEG Ratio | 59.10 | 23.52 |
| Price to Sales (TTM) | 4.00 | 5.88 |
| Price to Book (MRQ) | 1.55 | 2.70 |
| Market Capitalization | ||
| Market Capitalization | $1.85B | $141.13B |
| Enterprise Value | $1.61B | $156.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.48 | 6.53 |
| Enterprise to EBITDA | 25.92 | 20.84 |
| Risk & Other Metrics | ||
| Beta | 2.07 | 0.80 |
| Book Value per Share (MRQ) | $15.26 | $73.10 |
Financial Statements Comparison: Veracyte vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Revenue/Sales | $114.47M | $5.74B |
| Cost of Goods Sold | $34.97M | $2.23B |
| Gross Profit | $79.51M | $3.51B |
| Research & Development | $17.72M | $379.00M |
| Operating Income (EBIT) | $1.16M | $1.27B |
| EBITDA | $3.03M | $1.87B |
| Pre-Tax Income | $7.43M | $1.13B |
| Income Tax | $381,000 | $175.00M |
| Net Income (Profit) | $7.05M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Cash & Equivalents | $186.12M | $1.99B |
| Total Current Assets | $383.15M | $9.53B |
| Total Current Liabilities | $75.13M | $6.65B |
| Long-Term Debt | $43.09M | $15.98B |
| Total Shareholders Equity | $1.19B | $50.86B |
| Retained Earnings | $-436.94M | $44.91B |
| Property, Plant & Equipment | $70.15M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Operating Cash Flow | $18.76M | $1.47B |
| Capital Expenditures | $-1.82M | $-239.00M |
| Free Cash Flow | $3.54M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | VCYT | DHR |
|---|---|---|
| Shares Short | 6.11M | 7.84M |
| Short Ratio | 6.38 | 2.08 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 3,218,800 | 5,971,700 |
| Average Daily Volume (90 Day) | 1,752,003 | 4,520,667 |
| Shares Outstanding | 77.77M | 719.10M |
| Float Shares | 77.87M | 637.22M |
| % Held by Insiders | 0.01% | 0.11% |
| % Held by Institutions | 1.07% | 0.82% |
Dividend Analysis & Yield Comparison: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |